Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add filters








Language
Year range
1.
Rev. Inst. Med. Trop. Säo Paulo ; 57(4): 289-294, July-Aug. 2015. tab
Article in English | LILACS | ID: lil-761166

ABSTRACT

SUMMARYSporothrix schenckiiwas reclassified as a complex encompassing six cryptic species, which calls for the reassessment of clinical and epidemiological data of these new species. We evaluated the susceptibility of Sporothrix albicans(n = 1) , S. brasiliensis(n = 6) , S. globosa(n = 1), S. mexicana(n = 1) and S. schenckii(n = 36) to terbinafine (TRB) alone and in combination with itraconazole (ITZ), ketoconazole (KTZ), and voriconazole (VRZ) by a checkerboard microdilution method and determined the enzymatic profile of these species with the API-ZYM kit. Most interactions were additive (27.5%, 32.5% and 5%) or indifferent (70%, 50% and 52.5%) for TRB+KTZ, TRB+ITZ and TRB+VRZ, respectively. Antagonisms were observed in 42.5% of isolates for the TRB+VRZ combination. Based on enzymatic profiling, the Sporothrix schenckiistrains were categorized into 14 biotypes. Leucine arylamidase (LA) activity was observed only for S. albicansand S. mexicana. The species S. globosaand S. mexicanawere the only species without β-glucosidase (GS) activity. Our results may contribute to a better understanding of virulence and resistance among species of the genus Sporothrixin further studies.


RESUMOAvaliou-se a susceptibilidade de Sporothrix albicans(n = 1), S. brasiliensis(n = 1), S. globosa(n = 1), S. mexicana(n = 1) e S. schenckii(n = 36) frente à terbinafina (TRB) e a TRB em combinação com itraconazol (ITZ), cetoconazol (KTZ) e voriconazol (VRZ) pelo método de microdiluição ( checkerboard); o perfil enzimático destas espécies foi também avaliado, com base no kit API-ZYM. A maioria das interações foram aditivas (27,5%, 32,5% e 5%) ou indiferentes (70%, 50% e 52,5%) para TRB+KTZ, TRB+ITZ e TRB+VRZ, respectivamente. Antagonismo foi observado em 42,5% dos isolados para a combinação TRB+VRZ. Com base nos perfis enzimáticos, as cepas de Sporothrix schenckiievidenciaram 14 biotipos distintos. A atividade da leucina arilamidase (LA) só foi observada em S. albicanse S. mexicana.As espécies S. globosae S. mexicanaforam as únicas que não evidenciaram atividade da enzima β-glucosidase (GS). Estes resultados poderão contribuir para um melhor entendimento da virulência e resistência entre as espécies do gênero Sporothrixem futuros estudos.


Subject(s)
Humans , Animals , Cats , Antifungal Agents/pharmacology , Sporothrix/drug effects , Sporothrix/enzymology , Itraconazole/pharmacology , Ketoconazole/pharmacology , Microbial Sensitivity Tests , Naphthalenes/pharmacology , Phylogeny , Voriconazole/pharmacology
2.
Braz. j. microbiol ; 46(1): 125-129, 05/2015. tab
Article in English | LILACS | ID: lil-748244

ABSTRACT

In vitro interaction between tacrolimus (FK506) and four azoles (fluconazole, ketoconazole, itraconazole and voriconazole) against thirty clinical isolates of both fluconazole susceptible and -resistant Candida glabrata were evaluated by the checkerboard microdilution method. Synergistic, indifferent or antagonism interactions were found for combinations of the antifungal agents and FK506. A larger synergistic effect was observed for the combinations of FK506 with itraconazole and voriconazole (43%), followed by that of the combination with ketoconazole (37%), against fluconazole-susceptible isolates. For fluconazole-resistant C. glabrata, a higher synergistic effect was obtained from FK506 combined with ketoconazole (77%), itraconazole (73%), voriconazole (63%) and fluconazole (60%). The synergisms that we observed in vitro, notably against fluconazole-resistant C. glabrata isolates, are promising and warrant further analysis of their applications in experimental in vivo studies.


Subject(s)
Humans , Antifungal Agents/pharmacology , Azoles/pharmacology , Candida glabrata/drug effects , Drug Synergism , Tacrolimus/pharmacology , Candida glabrata/isolation & purification , Candidiasis/microbiology , Drug Resistance, Bacterial , Microbial Sensitivity Tests
3.
Mem. Inst. Oswaldo Cruz ; 107(3): 433-436, May 2012. tab
Article in English | LILACS | ID: lil-624029

ABSTRACT

The extensive use of azole antifungal agents has promoted the resistance of Candida spp to these drugs. Candida glabrata is a problematic yeast because it presents a high degree of primary or secondary resistance to fluconazole. In Brazil, C. glabrata has been less studied than other species. In this paper, we compared the activity of three major classes of antifungal agents (azoles, echinocandins and polyenes) against fluconazole-susceptible (FS) and fluconazole-resistant (FR) C. glabrata strains. Cross-resistance between fluconazole and voriconazole was remarkable. Among the antifungal agents, the echinocandins were the most effective against FS and FR C. glabrata and micafungin showed the lowest minimal inhibitory concentrations.


Subject(s)
Humans , Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Candida glabrata/drug effects , Echinocandins/pharmacology , Fluconazole/pharmacology , Pyrimidines/pharmacology , Triazoles/pharmacology , Candida glabrata/isolation & purification , Drug Resistance, Fungal/drug effects , Lipopeptides/pharmacology , Microbial Sensitivity Tests
4.
Braz. j. infect. dis ; 16(1): 78-81, Jan.-Feb. 2012. tab
Article in English | LILACS | ID: lil-614555

ABSTRACT

In the present study we used two groups of Candida dubliniensis strains: one containing fluconazole-susceptible clinical isolates and another containing fluconazole-resistant laboratory derivative from the former to examine the changes on susceptibility accompanying the development of resistance to fluconazole. Our findings confirmed the ability of C. dubliniensis isolates to become resistant to fluconazole and indicated that this resistance was crossed with ketoconazole, itraconazole, ravuconazole and terbinafine. We also tested combinations of terbinafine, amphotericin B, itraconazole and voriconazole against both groups of isolates in a checkerboard assay. Surprisingly, most combinations evidenced indifferent interactions, and the best synergism appeared when terbinafine and itraconazole were combined against the fluconazole-resistant group.


Subject(s)
Antifungal Agents/pharmacology , Candida/drug effects , Drug Resistance, Fungal/drug effects , Fluconazole/pharmacology , Candida/classification , Drug Synergism , Drug Therapy, Combination , Microbial Sensitivity Tests/methods
5.
Rev. Soc. Bras. Med. Trop ; 43(2): 205-206, Mar.-Apr. 2010.
Article in English | LILACS | ID: lil-545778

ABSTRACT

INTRODUCTION: The phospholipase activity in Candida albicans and Candida dubliniensis isolated from oral candidiasis cases were studied. METHODS: The phospholipase activity was evaluated in egg yolk agar. RESULTS: All the C. albicans isolates (n = 48) showed phospholipase activity (mean Pz = 0.66). However, none of the C. dubliniensis isolates (n = 24) showed this activity. CONCLUSIONS: The authors discuss whether these findings are a true characteristic of C. dubliniensis or a consequence of the methodology employed, which includes the possibility that NaCl may have inhibited the enzymatic activity of C. dubliniensis.


INTRODUÇÃO: Avaliou-se a atividade fosfolipásica em Candida albicans e Candida dubliniensis isoladas de casos de candidíase oral. MÉTODOS: A atividade de fosfolipase foi avaliada em ágar gema de ovo. RESULTADOS: Todos os isolados de C. albicans (nº = 48) evidenciaram atividade fosfolipásica (média Pz = 0.66). Todavia, nenhum isolado de C. dubliniensis (nº= 24) demonstrou esta atividade. CONCLUSÕES: Os autores discutem se estes achados são uma característica verdadeira de C. dubliniensis ou uma conseqüência da metodologia empregada, a qual inclui a possibilidade de que o NaCl seja inibidor da atividade enzimática de C. dubliniensis.


Subject(s)
Humans , Candida/enzymology , Candidiasis, Oral/microbiology , Phospholipases/metabolism , Candida albicans/enzymology , Candida albicans/pathogenicity , Candida/pathogenicity , Phospholipases/analysis
SELECTION OF CITATIONS
SEARCH DETAIL